Seven Stuff You Didn't Recognize Concerning AZD4547

The median number of cycles to first response was three, and 90% of responses were seen by the 6th cycle. A second phase III study was performed in patients with advanced MDS (Fenaux et?al, 2009). There was a statistically significant improvement in survival for the patients treated with azacitidine compared to conventional care regimens (24��4 vs. 15?months, P?=?0��0001). The heterogeneity of MDS has spurred interest in combining agents with different mechanisms of action to improve the frequency and robustness of responses. Extensive dysregulation of tumour necrosis factor �� (TNF-��), Fas, and TNF-related apoptosis-inducing ligand (TRAIL)-mediated signalling in MDS marrow leads to high rates of apoptosis http://www.selleckchem.com/products/AZD6244.html (Gersuk et?al, 1998). TNF-�� is a pro-inflammatory cytokine, and serves as a potent inhibitor of normal hematopoiesis (Selleri et?al, 1995). Etanercept is a soluble TNF-�� receptor which acts as a TNF-�� inhibitor. Initial studies with etanercept showed responses http://www.selleck.cn/products/azd4547.html in all three cell lines; the frequency of response to etanercept as a single agent was low (Deeg et?al, 2002). We hypothesized that the administration of azacitidine combined with etanercept might result in decreased myelosupression due to protection of non-clonal hematopoiesis and inhibition of survival in MDS clonal cells. Patients with a diagnosis of MDS and CMML according to the World Health Organization classification (Vardiman et?al, 2002) who had int-2 or high risk disease by the http://www.selleckchem.com/products/MK-1775.html International Prognostic Scoring System or who had low or int-1 risk disease with cytopenias (haemoglobin